Approved January 1998
Paroxysmal atrial fibrillation
Rymol (propafenone hydrochloride) has been approved for use in patients without structural heart disease, for prolongation of the time to recurrence of paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardia associated with disabling symptoms. The drug has been marketed in the U.S. since 1990 for patients with life-threatening ventricular arrhythmias.
In a 12-month study, patients' time to recurrence of paroxysmal atrial fibrillation/flutter, or sudden arrhythmic attacks, was eight times longer in patients receiving Rythmol versus patients treated with placebo.
The Rythmol drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.